<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Experience with high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (HDAC) in <z:e sem="disease" ids="C0279068" disease_type="Neoplastic Process" abbrv="">pediatric solid tumors</z:e> is limited </plain></SENT>
<SENT sid="1" pm="."><plain>Sixteen children with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> resistant to conventional therapies were registered in a pilot Pediatric <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (POG) study that required the administration of HDAC at 3 g/m2 every 12 hours for four doses </plain></SENT>
<SENT sid="2" pm="."><plain>There were four cases of <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo>, two cases of <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo>, four cases of <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>, and one case each of <z:mpath ids='MPATH_310'>germ cell tumor</z:mpath>, <z:hpo ids='HP_0002667'>Wilm's tumor</z:hpo>, <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo>, <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo>, and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> eligible patients had advanced diseases and had previously received extensive chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Thirteen patients received one course of HDAC and three patients received two courses of HDAC </plain></SENT>
<SENT sid="5" pm="."><plain>Due to prior treatments, patients had less than <z:mpath ids='MPATH_458'>normal</z:mpath> marrow reserves </plain></SENT>
<SENT sid="6" pm="."><plain>Short-term toxicity included <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, suppression of hemopoiesis, drug <z:hpo ids='HP_0001945'>fever</z:hpo>, and <z:hpo ids='HP_0003138'>increased blood urea nitrogen (BUN)</z:hpo>, <z:chebi fb="0" ids="16737">creatinine</z:chebi>, and liver enzymes </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> evaluable patients recovered from their toxicities </plain></SENT>
<SENT sid="8" pm="."><plain>There were no drug-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>None of the patients had neurologic problems, including the only patient with prior irradiation to the skull </plain></SENT>
<SENT sid="10" pm="."><plain>With the above schedule, HDAC appears to have manageable toxicity </plain></SENT>
</text></document>